A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer

PURPOSE: Our primary objective was to determine the benefit/risk of anthracycline-free regimens by comparing docetaxel + cyclophosphamide (TC) alone, fluorouracil + epirubicin + cyclophosphamide (FEC) followed by TC, or TC followed by FEC as a primary treatment for patients with HR-positive, HER2-ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishiguro, Hiroshi, Masuda, Norikazu, Sato, Nobuaki, Higaki, Kenji, Morimoto, Takashi, Yanagita, Yasuhiro, Mizutani, Makiko, Ohtani, Shoichiro, Kaneko, Koji, Fujisawa, Tomomi, Takahashi, Masato, Kadoya, Takayuki, Matsunami, Nobuki, Yamamoto, Yutaka, Ohno, Shinji, Takano, Toshimi, Morita, Satoshi, Tanaka-Mizuno, Sachiko, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103001/
https://www.ncbi.nlm.nih.gov/pubmed/32170634
http://dx.doi.org/10.1007/s10549-020-05590-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103001/
https://www.ncbi.nlm.nih.gov/pubmed/32170634
http://dx.doi.org/10.1007/s10549-020-05590-w

Ejemplares similares